Thorough group-wide efficiency improvements
First written in FY2016. 4 of 8 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2024-Q2.
The whole theme swung hardest in 2022: 8 of 40 companies on the "Worse" side.
32 other companies' latest entry also says "Advanced".
- FY2024-Q2AdvancedAnnual report
「We also worked to improve productivity throughout the group and controlled various expenses. As a result, revenue was ¥56,461 million, up 5.9% year on year, operating profit was ¥1,712 million, up 55.7%, ordinary profit was ¥1,692 million, up 36.2%, and net income attributable to owners of the parent was ¥861 million, up 71.5%.」
Group-wide productivity improvements and expense controls were pursued, resulting in year-on-year increases in operating profit and other figures. - FY2022RestatedAnnual report
「On the financial front, we will work to strengthen our financial position by improving the equity ratio through securing profits by implementing group-wide cost controls.」
The policy of group-wide cost controls, securing profits, and strengthening the financial position remains in place. - FY2021AdvancedAnnual report
「In terms of profit, although the dispensing pharmacy segment was affected by a decline in the number of prescriptions filled, efforts to promote the transition to generic drugs with reliable supply and favorable economics, improve operational efficiency and productivity, and reduce expenses resulted in operating profit of ¥3,429 million, up 112.3% year on year, and ordinary profit of ¥3,479 million, up 123.0%.」
Operational efficiency, productivity improvements, and expense reductions were pursued together with the transition to generic drugs, and the improvement in full-year operating profit and ordinary profit was reflected in the figures. - FY2021-Q3AdvancedAnnual report
「As a result of efforts to promote the transition to generic drugs with reliable supply and favorable economics, improve operational efficiency and productivity, and reduce expenses, operating profit was ¥2,773 million, up 125.7% year on year, and ordinary profit was ¥2,770 million, up 129.2%.」
Operational efficiency, productivity improvements, and expense reductions were pursued together with the transition to generic drugs, and the year-on-year improvement in operating profit and ordinary profit was reflected in the figures. - FY2021-Q2AdvancedAnnual report
「As a result of efforts to promote the transition to generic drugs with reliable supply and favorable economics, improve operational efficiency and productivity, and reduce expenses, operating profit was ¥1,355 million, up 70.1% year on year, ordinary profit was ¥1,397 million, up 78.1%, and net income attributable to owners of the parent was ¥578 million, up 165.1%.」
Operational efficiency, productivity improvements, and expense reductions were implemented together with the transition to generic drugs, and the year-on-year improvement in profit was reflected in the figures. - FY2018RestatedAnnual report
「We will improve cash flow, streamline the management structure, and strengthen our financial position.」
The policy of strengthening the financial position through cost and management-structure efficiency remains a basic policy of the Fifth Medium-Term Management Plan. - FY2017RestatedAnnual report
「In anticipation of future revisions to reimbursement rates, we will implement thorough cost controls.」
The policy of controlling costs in anticipation of future reimbursement revisions remains in place. - FY2016First statedAnnual report
「Thorough efficiency improvements」
Listed as one of the key initiatives.